📍 Indian Pharma Market | Post-Patent Trends | Anti-Diabetic Segment 📖 3-min read

The Indian Pharmaceutical Market (IPM) posted a healthy 7.8% growth in April 2025, driven by new launches and price hikes—especially in chronic segments like anti-diabetics. A key driver? The patent expiry of Empagliflozin, which opened the floodgates for generic competition.

Empagliflozin Brand Landscape Explodes Post-Patent

In just a few months, the number of Empagliflozin brands shot up from 86 to 147, with over 37 companies entering the market. While value growth was flat, volume surged 10%, making the treatment more accessible and affordable.

IPVentra Insight:

This case is a textbook example of what happens after patent cliffs in pharma. Once monopoly rights expire, the generic rush accelerates both market penetration and affordability—but also increases trademark, formulation, and regulatory complexity.